- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04783116
Plant Stanols and Liver Inflammation in Overweight and Obese Children
March 2, 2021 updated by: Maastricht University Medical Center
The Effects of Plant Stanol Ester Supplements on Liver Inflammation in Overweight and Obese Children
Obesity is associated with a variety of co-morbidities.
Children with obesity are more likely to have risk factors associated with cardiovascular diseases (CVD) and CVD risk markers (e.g.
hypertension, elevated serum cholesterol, and type 2 diabetes mellitus), but also with organ specific pathologies such as a non-alcoholic fatty liver disease (NAFLD).
A recent meta-analysis has shown that the prevalence of NAFLD in obese pediatric populations is approximately 35%, compared to approximately 8% in general pediatric population, making it a very important health threat in these populations.
Successful pharmacological interventions to treat or prevent NASH are not yet available and so far only weight loss has clear benefits.
However, it is well known that sustained weight-loss is difficult to achieve on the longer-term.
The investigators recently demonstrated in mice that plant sterol and stanol ester consumption inhibited the development of liver inflammation.
Moreover, Javanmardi et al. recently demonstrated in a population of adult NAFLD patients, that plasma concentrations of Alanine Transaminase (ALT) were reduced after daily plant sterol consumption (1.6 g/d) for 6 weeks.
In this study, the investigators propose to evaluate the effect of consuming soft chews enriched with plant stanol esters (3 grams/day) on ALT concentrations in children with overweight or (morbid) obesity who are at risk of developing NAFLD, in a randomized, placebo-controlled, double blinded study with an intervention period and follow-up period of 6 months.
52 overweight and obese children with elevated ALT concentrations (>39 U/L for boys and >33 U/L for girls) will be included.
All children will be randomly allocated to consume control or plant stanol ester enriched soft chews on a daily basis for a period of 6 months.
After 12 months there will be an additional blood sample to evaluate whether the 6 months intervention is still effective.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anita CE Vreugdenhil, MD, PhD
- Phone Number: 0031433875284
- Email: a.vreugdenhil@mumc.nl
Study Contact Backup
- Name: Judith W Lubrecht, MD
- Phone Number: 0031433875284
- Email: judith.lubrecht@mumc.nl
Study Locations
-
-
-
Maastricht, Netherlands
- Maastricht University Medical Center
-
Contact:
- Anita CE Vreugdenhil, MD, PhD
- Phone Number: 0031433875284
- Email: a.vreugdenhil@mumc.nl
-
Contact:
- Judith W Lubrecht, MD
- Phone Number: 0031433875284
- Email: judith.lubrecht@mumc.nl
-
Sub-Investigator:
- Judith W Lubrecht, MD
-
Sub-Investigator:
- Sabine Baumgartner, PhD
-
Sub-Investigator:
- Johanna Kreutz, MD
-
Principal Investigator:
- Anita CE Vreugdenhil, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participation in lifestyle intervention, provided by the Centre for Overweight Adolescent and Children Healthcare (COACH), at the Department of Pediatrics at the Maastricht University Medical Center (MUMC+).
- Age between 4-18 years old
- Plasma ALT concentrations above 39 U/L for boys and above 33 U/L for girls.
- Willingness to consume 6 soft chews on a daily basis, for a period of 6 months.
Exclusion Criteria:
- Presence of a severe medical condition, which contraindicates, in the investigators judgement, entry to the study.
- No signed informed consent by relevant parties (parents of children aged below 12 years, parents and or children aged between 12 and 16 years, or children aged 16 years and older).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Plant stanols (3g/day)
Consumption of plant stanol chews
|
Oral consumption of 6 plant stanol enriched chews per day for 6 months (total dosage is 3g/day).
Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
Other Names:
|
Placebo Comparator: Control
Consumption of placebo chews (without plant stanols)
|
Oral consumption of 6 placebo chews per day for 6 months.
Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in plasma ALT concentration at 6 and 12 months.
Time Frame: Baseline, 6 months and 12 months
|
Plasma ALT (Alanine Aminotransferase) concentration is a laboratory parameter, measured in blood, reflecting possible presence of NAFLD.
Concentrations below 26 U/L for boys, and below 22 U/L for girls, are considered normal.
Concentrations above 39 U/L for boys, and above 33 U/L are considered to reflect presence of NAFLD.
|
Baseline, 6 months and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in plasma AST and plasma CK-18 concentration at 6 and 12 months.
Time Frame: Baseline, 6 months and 12 months
|
Aspartate Aminotransferase (AST) and cytokeratin-18 (CK-18) are laboratory parameters, measured in the participants blood in U/L, reflecting liver health.
|
Baseline, 6 months and 12 months
|
Change in liver inflammation parameters at 6 and 12 months.
Time Frame: Baseline, 6 months and 12 months
|
Cathepsin-D and acid phosphatase are laboratory parameters, measured in mg/L in the participants blood, reflecting liver inflammation.
|
Baseline, 6 months and 12 months
|
Change in lipid metabolism parameters at 6 and 12 months.
Time Frame: Baseline, 6 months and 12 months
|
Serum total cholesterol, HDL cholesterol, triacylglycerol (TAG) with correction for free glycerol and non-esterified fatty acids (NEFA) are laboratory parameters, measured in mmol/L in the participants blood, reflecting their lipid metabolism.
|
Baseline, 6 months and 12 months
|
Change in lipid protein metabolism parameters at 6 and 12 months.
Time Frame: Baseline, 6 months and 12 months
|
ApoA1 and apoB100 plasma concentrations are laboratory parameters, measured in g/L in the participants blood, reflective of the lipoprotein metabolism.
|
Baseline, 6 months and 12 months
|
Change in plasma glucose concentration at 6 and 12 months.
Time Frame: Baseline, 6 months and 12 months
|
Fasting glucose is a laboratory parameter, measured in mmol/L in the participants blood, reflecting glucose metabolism.
|
Baseline, 6 months and 12 months
|
Change in plasma insulin concentration at 6 and 12 months.
Time Frame: Baseline, 6 months and 12 months
|
Fasting insulin concentrations is a laboratory parameters, measured in mU/L in the participants blood, reflecting glucose metabolism.
|
Baseline, 6 months and 12 months
|
Change in insulin sensitivity at 6 and 12 months.
Time Frame: Baseline, 6 months and 12 months
|
Insulin sensitivity will be calculated using the HOMA-IR formula (homeostatis model) which is (fasting glucose*fasting insulin) /22,5.
As HOMA-IR is a ratio, it does not have a unit.
|
Baseline, 6 months and 12 months
|
Change in non-cholesterol sterol and oxy(phyto)sterol concentrations at 6 and 12 months.
Time Frame: Baseline, 6 months and 12 months
|
A panel of non-cholesterol sterols, as surrogate markers for cholesterol absorption and synthesis will be measured in the participants blood.
|
Baseline, 6 months and 12 months
|
Change in plasma inflammatory markers at 6 and 12 months.
Time Frame: Baseline, 6 months and 12 months
|
Plasma concentrations of CRP and high sensitivity CRP will be measured in mg/L in the participants blood, to assess presence of low-grade inflammation in the body.
|
Baseline, 6 months and 12 months
|
Change in ultrasonographic hepatorenal index (HRI) at 6 and 12 months.
Time Frame: Baseline, 6 months and 12 months
|
HRI is measured during a conventional ultrasound of the liver, in which three close-up images of the liver and right kidney are made by a physician-researcher. HRI is calculated from these images by a pediatric radiologist, as the ratio of the hepatic brightness and the renal brightness (HRI = echogenicity of the liver/echogenicity of the kidney).
The average of the three images is taken as the definite HRI, as a reflection of hepatic fat content.
|
Baseline, 6 months and 12 months
|
Change in continuous Controlled Attenuation Parameter (CAP) at 6 and 12 months.
Time Frame: Baseline, 6 months and 12 months
|
CAP is measured during a vibration controlled transient elastography of the liver, which is performed with a Fibroscan by a physician-researcher.
The value is a reflection of hepatic fat content.
|
Baseline, 6 months and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 15, 2021
Primary Completion (Anticipated)
December 31, 2022
Study Completion (Anticipated)
December 31, 2022
Study Registration Dates
First Submitted
February 23, 2021
First Submitted That Met QC Criteria
March 2, 2021
First Posted (Actual)
March 5, 2021
Study Record Updates
Last Update Posted (Actual)
March 5, 2021
Last Update Submitted That Met QC Criteria
March 2, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL73527.000.20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Obesity
-
Virginia Commonwealth UniversityActive, not recruitingObesity, PediatricUnited States
-
University of British ColumbiaThe Hospital for Sick Children; Canadian Institutes of Health Research (CIHR); Alberta Health services and other collaboratorsCompleted
-
Hasselt UniversityJessa HospitalCompletedObesity, Pediatric
-
Azienda Ospedaliera Universitaria Integrata VeronaNot yet recruitingObesity, Pediatric
-
University of British ColumbiaHeart and Stroke Foundation of Canada; Public Health Agency of Canada (PHAC); Childhood Obesity Foundation and other collaboratorsCompleted
-
Columbia UniversityCompletedVitamin D Deficiency | Obesity, Morbid | Obesity, Childhood | Obesity, PediatricUnited States
-
University Hospital, Clermont-FerrandAME2P Laboratory, Clermont Auvergne UniversityCompleted
-
Medical College of WisconsinWisconsin Department of Health and Family Services; Children's Health System...TerminatedPediatric Obesity | Pediatric OverweightUnited States
-
Kahramanmaras Sutcu Imam UniversityCompletedPediatric Obesity | Pediatric DentistryTurkey
-
Central Hospital, Nancy, FranceNot yet recruiting
Clinical Trials on Plant stanols (3g/day)
-
Raisio GroupUniversity of TurkuCompletedDyslipidemias | Hypercholesterolemia | Hyperlipidemias
-
Maastricht University Medical CenterRaisio Nutrition Ltd.Completed
-
University of HelsinkiUniversity of Eastern FinlandUnknown
-
Maastricht University Medical CenterRaisio Group; TKI Life Sciences and Health (LSH)RecruitingCardiovascular Diseases | Asthma, AllergicNetherlands
-
Chonbuk National University HospitalCompleted
-
Maastricht University Medical CenterCompleted
-
Chang Gung Memorial HospitalCompleted
-
Casa Sollievo della Sofferenza IRCCSUniversity of FoggiaCompleted
-
Florida State UniversityNOW FoodsCompletedHypertension | Obesity | Pre-hypertensionUnited States